Patients' Attitudes Towards Open-Label Placebo Implementation Into Clinical Practice (PATOLP)

University Hospital Basel

Status

Completed

Conditions

Open-label Placebos

Treatments

Other: focus group discussions (FGD)

Study type

Observational

Funder types

Other

Identifiers

NCT05166213

2021-02304 ex21Frey;

Details and patient eligibility

About

The aim of this project is to assess patients' opinions, attitudes, and ideas regarding the administration of OLPs in clinical practice, although they might never have had contact to placebos. A qualitative approach is used and online focus group discussions (FGD) with patients with different clinical conditions, entailing chronic back pain, Parkinson's disease, chronic migraine, chemotherapy induced emesis, and menopausal complaints are conducted.

Full description

Substantial placebo effects have been known for several decades for a multitude of physical as well as psychological complaints. It is essential to test the acceptability of Open-label placebos (OLPs) of patients and health professionals. The aim of this project is to assess patients' opinions, attitudes, and ideas regarding the administration of OLPs in clinical practice, although they might never have had contact to placebos. A qualitative approach is used and online focus group discussions (FGD) with patients with different clinical conditions, entailing chronic back pain, Parkinson's disease, chronic migraine, chemotherapy induced emesis, and menopausal complaints are conducted. A semi-structured topic guide with open-ended questions will be used.

Enrollment

6 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Signed informed Consent form (see Appendix)
Capable of consent (language/cognitive)
At least 18 years of age
Ability to attend an online conference in regard of physical and psychological condition and technical knowhow and equipment
In addition, participants have to be affected by one of the following conditions/disorders:
- Chronic back pain
- Chemotherapy-induced emesis (last occurrence at least before 14 days and at maximum before one year)
- Chronic migraine
- Parkinson's disease
- Clinically significant menopausal complaints

Exclusion criteria

Severe ailment and medication side-effects which would interfere with study participation (e.g., due to concentration impairment)
Acute psychological crisis which would affect study participation essentially or suicidality
Co-morbidity that overlaps in symptoms with the symptoms necessary for inclusion
Essential psychiatric disorders other than moderate depression